Grail Inc. Price Targets Cut Amid Trial Disappointment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy GRAL?
Source: stocktwits
- Price Target Cuts: Canaccord lowered Grail Inc.'s price target from $105 to $80 while maintaining a 'Buy' rating, indicating continued confidence in the company's long-term prospects despite recent setbacks.
- Trial Outcome Impact: Baird analyst Catherine Ramsey Schulte reduced Grail's price target from $113 to $82, reflecting updates to financial models based on the Galleri blood test results, yet did not downgrade the stock, suggesting optimism about future performance.
- Market Overreaction: Canaccord acknowledged disappointment with the NHS-Galleri study's topline findings but argued that the nearly 50% drop in after-hours trading represents an overreaction, maintaining a constructive view on the broader data set.
- Stock Performance: Despite the challenges, Grail Inc.'s stock has gained over 112% in the past 12 months, indicating sustained market interest in its long-term commercial potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GRAL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GRAL
Wall Street analysts forecast GRAL stock price to fall
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 101.530
Low
38.00
Averages
60.86
High
83.71
Current: 101.530
Low
38.00
Averages
60.86
High
83.71
About GRAL
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GRAIL's Cancer Screening Trial Misses Primary Endpoint
- Trial Results Disappoint: GRAIL's Galleri multi-cancer screening trial within the NHS failed to meet its primary endpoint, resulting in a 48% drop in after-hours trading, indicating strong market reaction to the clinical trial outcomes.
- Detection Rate Improvement: Although the trial did not show a statistically significant reduction in Stage III-IV cancers, GRAIL highlighted a meaningful decrease in Stage IV diagnoses when combining Galleri with standard care across 12 deadly cancers, suggesting potential for early cancer detection.
- Strong Financial Performance: GRAIL reported a 14% year-over-year increase in Q4 total revenue to $43.6 million, surpassing analyst expectations of $43.48 million, despite a net loss of $99.2 million, demonstrating resilience in revenue growth.
- Market Sentiment Shift: On Stocktwits, retail sentiment around GRAL shares surged from 'bullish' to 'extremely bullish' in the past 24 hours, with message volume remaining at 'extremely high' levels, reflecting investor interest in the company's future potential.
See More
Grail Shares Drop 50% Following Earnings Report, Attributed to Test Results.
- Stock Performance: Grail's stock fell approximately 50% in after-hours trading following disappointing results from its cancer trial.
- Investor Reaction: The negative trial outcomes led to significant investor disappointment, impacting the company's market valuation.
See More
Grail Inc. Price Targets Cut Amid Trial Disappointment
- Price Target Cuts: Canaccord lowered Grail Inc.'s price target from $105 to $80 while maintaining a 'Buy' rating, indicating continued confidence in the company's long-term prospects despite recent setbacks.
- Trial Outcome Impact: Baird analyst Catherine Ramsey Schulte reduced Grail's price target from $113 to $82, reflecting updates to financial models based on the Galleri blood test results, yet did not downgrade the stock, suggesting optimism about future performance.
- Market Overreaction: Canaccord acknowledged disappointment with the NHS-Galleri study's topline findings but argued that the nearly 50% drop in after-hours trading represents an overreaction, maintaining a constructive view on the broader data set.
- Stock Performance: Despite the challenges, Grail Inc.'s stock has gained over 112% in the past 12 months, indicating sustained market interest in its long-term commercial potential.
See More
GRAIL Reports Q4 Earnings Beat Expectations
- Earnings Highlights: GRAIL reported a Q4 GAAP EPS of -$2.44, beating expectations by $0.22, indicating improvements in financial management despite ongoing losses.
- Revenue Growth: The company achieved $43.6 million in revenue for Q4, a 14% year-over-year increase that surpassed market expectations by $122,000, reflecting sustained product acceptance in the market.
- Galleri Sales Performance: Revenue from Galleri grew 31% year-over-year to $41.3 million, demonstrating strong market demand in the cancer screening sector and further solidifying its market position.
- Future Outlook: GRAIL reiterated its 2026 sales growth guidance for Galleri at 22%-32% while planning to expand its sales force post-NHS-Galleri trial, showcasing confidence in future growth opportunities.
See More
Grail Announces NHS-Galleri Trial Topline Results
- Trial Overview: Grail's NHS-Galleri trial results did not show a statistically significant reduction in Stage III-IV cancers, yet a favorable trend was observed in a pre-specified group of 12 deadly cancers, indicating the potential of multi-cancer screening.
- Reduction in Diagnoses: The addition of the Galleri test to standard screening resulted in a clinically meaningful reduction in Stage IV diagnoses across the specified cancers, with over a 20% decrease noted in the second and third rounds, demonstrating the effectiveness of the screening approach.
- Market Reaction: Grail's shares plummeted 47% to $53.33 in premarket trading, reflecting disappointment in the trial results, although the company remains optimistic about future sales growth.
- Future Plans: Grail is expanding its sales and medical teams to bolster education and support for Galleri, based on promising preliminary data from the NHS-Galleri trial, which highlights the potential for multi-cancer early detection.
See More
Comfort Systems Reports Strong Earnings Beat
- Earnings Beat: Comfort Systems reported earnings of $9.37 per share, surpassing the analyst consensus estimate of $6.75, indicating a significant improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $2.646 billion, exceeding the analyst consensus estimate of $2.337 billion, reflecting strong market demand and driving overall performance.
- Positive Stock Reaction: Comfort Systems shares jumped 4.6% to $1,436.25 in pre-market trading, indicating a favorable market response to the earnings report, which may attract more investor interest.
- Optimistic Market Outlook: The strong earnings data not only enhances the company's short-term stock price but also lays the groundwork for future growth, increasing market attractiveness for long-term investments in Comfort Systems.
See More
GRAIL's Cancer Screening Trial Misses Primary Endpoint
- Trial Results Disappoint: GRAIL's Galleri multi-cancer screening trial within the NHS failed to meet its primary endpoint, resulting in a 48% drop in after-hours trading, indicating strong market reaction to the clinical trial outcomes.
- Detection Rate Improvement: Although the trial did not show a statistically significant reduction in Stage III-IV cancers, GRAIL highlighted a meaningful decrease in Stage IV diagnoses when combining Galleri with standard care across 12 deadly cancers, suggesting potential for early cancer detection.
- Strong Financial Performance: GRAIL reported a 14% year-over-year increase in Q4 total revenue to $43.6 million, surpassing analyst expectations of $43.48 million, despite a net loss of $99.2 million, demonstrating resilience in revenue growth.
- Market Sentiment Shift: On Stocktwits, retail sentiment around GRAL shares surged from 'bullish' to 'extremely bullish' in the past 24 hours, with message volume remaining at 'extremely high' levels, reflecting investor interest in the company's future potential.
See More
Grail Shares Drop 50% Following Earnings Report, Attributed to Test Results.
- Stock Performance: Grail's stock fell approximately 50% in after-hours trading following disappointing results from its cancer trial.
- Investor Reaction: The negative trial outcomes led to significant investor disappointment, impacting the company's market valuation.
See More
Grail Inc. Price Targets Cut Amid Trial Disappointment
- Price Target Cuts: Canaccord lowered Grail Inc.'s price target from $105 to $80 while maintaining a 'Buy' rating, indicating continued confidence in the company's long-term prospects despite recent setbacks.
- Trial Outcome Impact: Baird analyst Catherine Ramsey Schulte reduced Grail's price target from $113 to $82, reflecting updates to financial models based on the Galleri blood test results, yet did not downgrade the stock, suggesting optimism about future performance.
- Market Overreaction: Canaccord acknowledged disappointment with the NHS-Galleri study's topline findings but argued that the nearly 50% drop in after-hours trading represents an overreaction, maintaining a constructive view on the broader data set.
- Stock Performance: Despite the challenges, Grail Inc.'s stock has gained over 112% in the past 12 months, indicating sustained market interest in its long-term commercial potential.
See More
GRAIL Reports Q4 Earnings Beat Expectations
- Earnings Highlights: GRAIL reported a Q4 GAAP EPS of -$2.44, beating expectations by $0.22, indicating improvements in financial management despite ongoing losses.
- Revenue Growth: The company achieved $43.6 million in revenue for Q4, a 14% year-over-year increase that surpassed market expectations by $122,000, reflecting sustained product acceptance in the market.
- Galleri Sales Performance: Revenue from Galleri grew 31% year-over-year to $41.3 million, demonstrating strong market demand in the cancer screening sector and further solidifying its market position.
- Future Outlook: GRAIL reiterated its 2026 sales growth guidance for Galleri at 22%-32% while planning to expand its sales force post-NHS-Galleri trial, showcasing confidence in future growth opportunities.
See More
Grail Announces NHS-Galleri Trial Topline Results
- Trial Overview: Grail's NHS-Galleri trial results did not show a statistically significant reduction in Stage III-IV cancers, yet a favorable trend was observed in a pre-specified group of 12 deadly cancers, indicating the potential of multi-cancer screening.
- Reduction in Diagnoses: The addition of the Galleri test to standard screening resulted in a clinically meaningful reduction in Stage IV diagnoses across the specified cancers, with over a 20% decrease noted in the second and third rounds, demonstrating the effectiveness of the screening approach.
- Market Reaction: Grail's shares plummeted 47% to $53.33 in premarket trading, reflecting disappointment in the trial results, although the company remains optimistic about future sales growth.
- Future Plans: Grail is expanding its sales and medical teams to bolster education and support for Galleri, based on promising preliminary data from the NHS-Galleri trial, which highlights the potential for multi-cancer early detection.
See More
Comfort Systems Reports Strong Earnings Beat
- Earnings Beat: Comfort Systems reported earnings of $9.37 per share, surpassing the analyst consensus estimate of $6.75, indicating a significant improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $2.646 billion, exceeding the analyst consensus estimate of $2.337 billion, reflecting strong market demand and driving overall performance.
- Positive Stock Reaction: Comfort Systems shares jumped 4.6% to $1,436.25 in pre-market trading, indicating a favorable market response to the earnings report, which may attract more investor interest.
- Optimistic Market Outlook: The strong earnings data not only enhances the company's short-term stock price but also lays the groundwork for future growth, increasing market attractiveness for long-term investments in Comfort Systems.
See More
